Validation of B’SYS KV3.x cell lines using automated and manual patch-clamp electrophysiology

KV3.x receptors have recently emerged as potential targets for treatment of a variety of CNS disorders, including epilepsy, ataxias, hearing disorders, schizophrenia and cognitive impairments. KV3.1–KV3.4 protein isoforms contribute to the high-frequency firing of neurons such as auditory brain stem neurons, fast-spiking cortical and hippocampal GABAergic interneurons, and Purkinje cells of the cerebellum, and play an important role in the regulation of intrinsic excitability and neurotransmitter release at presynaptic terminals of many neurons.

B’SYS has generated a panel of cell lines stably transfected with KV3.1a/b, KV3.2, KV3.3 and KV3.4 subunits. Using automated (QpatchTM ) as well as manual patch-clamp recordings, the aim of this validation study was to characterize these cell lines pharmacologically using the selective serotonin
reuptake inhibitor paroxetine. In addition, the effect of KV modulator 1 was investigated on KV3.1b.